EGFR and non-small cell lung carcinoma: Other EGFR mutations (HR 1.68, 95% CI 1.18–2.39, P = 0.004), and ECOG PS ≥ 2 (HR 1.31, 95% CI 1.06–1.62, P = 0.012), and baseline BM (HR 1.64, 95% CI 1.38–1.94, P < 0.001) were identified as independent risk factors of treatment failure in NSCLC patients with EGFR-activating mutations who received EGFR-TKIs as first-line treatment.